Cholecystokinin (cck) Or Derivative Patents (Class 514/12.6)
  • Patent number: 10391074
    Abstract: A composition for pain relief including synergistically effective amounts of an amino benzoate local anesthetic, methylsulfonylmethane (MSM), and ethoxydiglycol. A method of treating pain, by applying the composition to skin in an area of pain, and blocking nerve signals. A method of improving range of motion in an individual, by applying the composition to skin, relieving pain, and allowing the individual to have an improved range of motion at an area of pain.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: August 27, 2019
    Assignee: Sambria Pharmaceuticals, LLC
    Inventor: Michael Harvey Greenspan
  • Patent number: 9974861
    Abstract: The present invention relates to formulation precursors (pre-formulations) for the in situ generation of compositions for the controlled release of the salts of peptide active agents, including somatostatin analogues. The invention also relates to pre-formulations of amphiphilic components and at least one salt of a peptide active agent (e.g., somatostatin analogue) for parenteral application.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: May 22, 2018
    Assignee: CAMURUS AB
    Inventors: Markus Johnsson, Fredrik Joabsson, Catalin Nistor, Krister Thuresson, Fredrik Tiberg
  • Publication number: 20140045755
    Abstract: The present invention relates to a method for preventing or ameliorating a sleep-related breathing disorder. The method involves the use of one or a combination of cholecystokinin (CCK) receptor antagonists.
    Type: Application
    Filed: October 21, 2013
    Publication date: February 13, 2014
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: David W. Carley, Miodrag Radulovacki
  • Publication number: 20130196908
    Abstract: The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.
    Type: Application
    Filed: March 13, 2013
    Publication date: August 1, 2013
    Applicant: TRIGEMINA, INC.
    Inventor: TRIGEMINA, INC.
  • Patent number: 8445439
    Abstract: The present invention provides an itch suppressant containing cholecystokinin 2 receptor agonist such as a peptide having an amino acid sequence homologous with a partial amino acid sequence of at least seven C-terminal amino acids of the peptide having the amino acid sequence represented by SEQ:ID No. 1 as an active ingredient as a rapid-acting itch suppressant effective in treating skin illnesses associated with strong itch such as atopic dermatitis having few side effects. [SEQ:?ID?No.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: May 21, 2013
    Assignee: University of Occupational and Environmental Health, Japan
    Inventors: Yoshiki Tokura, Shoko Fukamachi
  • Publication number: 20120179090
    Abstract: Described herein is a transmucosal delivery device and their use for delivering bioactive agents across a mucosal membrane. The delivery devices contain a pharmaceutically acceptable oxidizing and agents that facilitates the delivery of the blood stream across the mucosal membrane.
    Type: Application
    Filed: January 3, 2012
    Publication date: July 12, 2012
    Inventors: Totada Shantha, Jessica Shantha, Erica Shantha, Lauren Shantha
  • Publication number: 20120148529
    Abstract: The present invention relates to the use of inclusion bodies as vehicles for therapeutic protein delivery. This method is applicable to the delivery of therapeutic proteins to intracellular locations. In addition, the invention also relates to the administration of a cell or a pharmaceutical composition comprising inclusion bodies formed by therapeutic proteins. These inclusion bodies formed by therapeutic proteins could be used for the treatment of different diseases.
    Type: Application
    Filed: May 12, 2010
    Publication date: June 14, 2012
    Applicants: Centro de Invesigacion Biomedica en Red en Bioiagenieria, Biomateriales, y Nanomedicina (Cibe, Universitat Autonoma de Barcelona et al.
    Inventors: Elena Garcia-Fruitos, Esther Vazquez Gomez, Jose Luis Corchero, Antonio Pedro Villa Verde Corrales
  • Publication number: 20120058938
    Abstract: The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body. In particular, the invention concerns the use of a nutritional composition for the treatment of a disorder, which is mediated by a postprandial endocrine or neurological response in a human body, wherein the nutritional composition comprises one or more of a specific protein fraction, a specific carbohydrate fraction and a specific nutritional fiber fraction.
    Type: Application
    Filed: March 9, 2010
    Publication date: March 8, 2012
    Applicant: N.V. NUTRICIA
    Inventors: Robert Johan Joseph Hageman, Mirian Lansink
  • Publication number: 20120035100
    Abstract: Disclosed herein are compositions and methods for treating obesity involving satiation gut peptide administration to the mouth of a subject for a predetermined dose and frequency. In other embodiments, materials and methods of treating certain psychological disorders are disclosed involving satiation gut peptides. In exemplary embodiments, the satiation gut peptide pertains to PYY.
    Type: Application
    Filed: January 21, 2010
    Publication date: February 9, 2012
    Inventors: Sergei Zolotukhin, Andres Acosta
  • Publication number: 20110257087
    Abstract: The present invention provides protein hydrolysate compositions having enhanced cholecystokinin (CCK) releasing activity that can be used to promote satiety.
    Type: Application
    Filed: December 30, 2009
    Publication date: October 20, 2011
    Applicant: SOLAE, LLC
    Inventors: Elaine Krul, Theodore M. Wong, Jason F. Lombardi, Charles S. Schasteen
  • Publication number: 20110136737
    Abstract: The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Application
    Filed: August 17, 2007
    Publication date: June 9, 2011
    Inventors: Odile Esther Levy, Alain D. Baron, Lawrence J. D'Souza, Mary Erickson, Soumitra S. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young, Thao Le
  • Publication number: 20110039768
    Abstract: The present invention relates to a fish protein hydrolysate containing molecules capable of exerting a satietogenic activity and of regulating food intake in humans or animals. More specifically, the protein hydrolysate according to the invention enables stimulation of the secretion of endogenous cholescystokinins (CCKs) and of endogenous glucagon-like peptide 1 (GLP1) molecules by intestinal cells and the supply of exogenous CCKs. The fish protein hydrolysate according to the invention is obtained by enzymatic hydrolysis of at least one protein source selected from the group composed of the pelagic fish species Micromesistius poutassou, Clupea harengus, Scomber scombrus, Sardina pilchardus, Trisopterus esmarki and Trachurus spp.
    Type: Application
    Filed: February 12, 2009
    Publication date: February 17, 2011
    Inventors: Hubert Drieu La Rochelle, Elisa Courois, Benoit Cudennec, Martine Fouchereau-Peron, Rozenn Ravallec-Ple
  • Publication number: 20110034377
    Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Application
    Filed: April 23, 2010
    Publication date: February 10, 2011
  • Publication number: 20110021426
    Abstract: The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.
    Type: Application
    Filed: July 27, 2010
    Publication date: January 27, 2011
    Inventors: Lawrence R. TOLL, David C. YEOMANS, Martin S. ANGST, Daniel I. JACOBS
  • Publication number: 20100297066
    Abstract: Novel biodegradable compositions are disclosed. The biodegradable compositions include at least one hydroxyl-terminated component and at least one bioactive peptide in a linear chain. The compositions may be utilized as medical devices including drug delivery devices, tissue adhesives and/or sealants.
    Type: Application
    Filed: May 14, 2008
    Publication date: November 25, 2010
    Inventors: Joshua B. Stopek, Brian Cuevas
  • Publication number: 20100239554
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Application
    Filed: February 3, 2010
    Publication date: September 23, 2010
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wel Wang, Benjamin Spink, Willem P. Stemmer, Nathan C. Geething, Wayne To, Jeffrey L. Cleland